Literature DB >> 3261393

In vivo competition between self peptides and foreign antigens in T-cell activation.

L Adorini1, S Muller, F Cardinaux, P V Lehmann, F Falcioni, Z A Nagy.   

Abstract

Cytotoxic and helper T lymphocytes recognize foreign antigen in the form of short peptides associated with class I and class II major histocompatibility complex (MHC) molecules, respectively. A recent study of the three-dimensional structure of a class I MHC molecule revealed a cleft formed by the amino-terminal half of the protein, which could serve as the binding site for these peptides. Because an individual possesses only a limited set of different MHC molecules, each molecule of this set must have the ability to bind a large number of different peptides in order to ensure full immunocompetence. Thus, it can be anticipated that peptides with unrelated sequences compete for binding to the same MHC molecule, and, indeed, this has been shown to occur in vitro. We therefore decided to see whether such competition could also regulate the cell responses in vivo. We have found that a synthetic peptide corresponding to residues 46-62 of mouse lysozyme, although not immunogenic itself, effectively inhibits the priming for T-cell responses when injected into mice together with foreign protein or peptide antigens. The inhibition observed strictly correlates with the capacity of the competitor to bind to the particular MHC molecule presenting the foreign antigen, and its extent depends on the molar ratio between antigen and competitor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261393     DOI: 10.1038/334623a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  44 in total

Review 1.  Inhibition of T cell responses by transferrin-coupled competitor peptides.

Authors:  Lolita Zaliauskiene; Rebecca L Fazio; Sunghyun Kang; Kerri Sparks; Casey T Weaver; Kurt R Zinn; James F Collawn
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Mechanisms of transplantation immunity.

Authors:  E Simpson
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  A role for major histocompatibility complex-binding peptides in the immunotherapy of autoimmune disease.

Authors:  D C Wraith; D E Smilek
Journal:  Springer Semin Immunopathol       Date:  1992

Review 4.  Approaches toward peptide-based immunotherapy of autoimmune diseases.

Authors:  L Adorini; J C Guéry; S Trembleau
Journal:  Springer Semin Immunopathol       Date:  1992

Review 5.  What future for therapeutic prevention of type 1 (insulin-dependent) diabetes mellitus?

Authors:  P Pozzilli; A Signore; D Andreani
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

6.  Cellular immune response to the antigen administered as an immune complex in vivo.

Authors:  S Marusić-Galesić; M Marusić; B Pokrić
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

7.  Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease.

Authors:  Jiang Xia; Elin Bergseng; Burkhard Fleckenstein; Matthew Siegel; Chu-Young Kim; Chaitan Khosla; Ludvig M Sollid
Journal:  Bioorg Med Chem       Date:  2007-07-25       Impact factor: 3.641

Review 8.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

9.  Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen.

Authors:  D E Speiser; T Zürcher; H Ramseier; H Hengartner; P Staeheli; O Haller; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  An unexpectedly labile mitochondrially encoded protein is required for Mta expression.

Authors:  A C Han; J R Rodgers; R R Rich
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.